Healthy or Under-Screened Dense Breast Tissue by Lisa Malia Norman, MSM, CEO

There's a term I heard often once I was diagnosed with breast cancer: "the diseased breast." That's how the oncologists, radiologists, and surgeons referred to my right breast, in appointment after appointment. My right breast had shown an area of concern on imaging, which led to an ultrasound, then a biopsy, then the word every woman fears hearing about herself.

My left breast, in all of those same conversations, was called something else. -- "The healthy breast."

I want to tell you why that phrase has stayed with me — and why I’m naming The Healthy Breast report after it.

Extremely Dense, on Both Sides

Both of my breasts were dense. Extremely dense, in fact — the kind of tissue that shows up white on a mammogram, the same color cancer shows up as, making it genuinely difficult to see any cancer hiding inside. That density was true on both sides. But only one side had raised a flag. So only one side got a name that meant "something is wrong here," and the other got a name that meant "you're safe."

I built an entirely new team of doctors to get the treatment I believed I needed. My original team — highly recommended, well credentialed — thought a double mastectomy was too aggressive. They recommended a lumpectomy, radiation, and ten years of tamoxifen instead. 

I didn't agree. 

Something in me knew this wasn't going to be my only encounter with this disease, and I wanted to remove as much risk as I possibly could. So I fired that team, and built a new one willing to support the choice that felt right to me — even though it was still an incredibly hard decision to make with the information we had at the time.

Through all of it — the imaging, the consultations, the additional scans done specifically to prepare for surgery 

— no one ever found any sign of cancer in my "healthy" breast.

What the Pathology Lab Found - Healthy or Under-Screened Dense Breast Tissue

It wasn't until after the double mastectomy, when both breasts were sent to pathology, that the truth came out. My left breast — the healthy one — was loaded with cancer. Multi-quadrant. Multifocal. What had looked clear on every scan turned out to be bilateral breast cancer, hiding in plain sight the entire time, undetected by every tool we had used to look for it.

I remember getting that call from my surgeon. I remember sitting down, finally, because my legs wouldn't hold me. I remember thinking: if I hadn't advocated for more than what was being recommended, that cancer would still be there right now, growing, unnamed and untreated.

The Name Is a Hope, Not a Claim

That's why this report carries the name it does. Not because I believe "healthy breast" is an accurate label — my own body is proof that it so often isn't. I chose it because it's what I want to be true. I want every breast called healthy to actually be healthy, not just under-screened. I want the word "healthy" to be something we've earned through real information, not under-screened dense breast tissue and not something we've assumed because nothing alarming happened to show up yet.

If my screening had been better — if the technology and the process had matched the density of my tissue — my left breast would never have been called healthy in the first place. It would have been flagged and breast cancer found. Named. Treated. 

The decision in front of me would have been made with better information and it wouldn't have needed to be made almost entirely on intuition and advocacy, against the advice of doctors who came highly recommended and simply didn't see what I somehow already knew was there.

I got the outcome I needed. I built the team that listened to me, made the choice that felt right, and it turned out to be the choice that likely saved my life. 

But I am acutely aware of how much of that came down to persistence, resources, and no small amount of luck. 

So many women don't get that same chance. 

They don't have the ability to rebuild a medical team from scratch, or the confidence to override a highly recommended plan, or a mother who'd walked the same road and could tell them what she wished she'd known. 

They are told they're healthy, and they believe it, because why wouldn't they?

Why This Work Matters

This report exists because "healthy" should never be a guess dressed up as a diagnosis. It should be something we can actually verify — through better screening, better tools, and better information handed to women before they're standing in a doctor's office trying to make life-altering decisions with an incomplete picture.

Every woman deserves to know, as early and as clearly as possible, what's actually happening in her body. Not what the density of her tissue allows a mammogram to see. Not what fits neatly into a standard protocol. The truth — the whole truth — about both breasts, healthy or not.

That's what we're building toward. That's why it's called The Healthy Breast Report – we’re building it now and revealing it, this October at The Breast Density Summit. You can help by bringing it directly to your community, screening center or organization today.

The Breast Density Summit brings together patients, physicians, researchers, and industry leaders for a day dedicated to elevating the conversations, innovations, access and delivery of care when screening breast density — its role in cancer risk, the limits of standard mammography, and what patients need to know to advocate for themselves. The summit combines expert panels, patient stories, and actionable next steps for attendees and the broader healthcare community.

Register, Donate, Partner or Sponsor

This inaugural summit will host the Bay Area launch of the Clear Pathways Program, an initiative dedicated to closing the gap women with dense breast tissue face in receiving timely, appropriate follow-up care. Clear Pathways works to standardize the journey from a breast density finding through supplemental screening and diagnosis — removing the confusion and delay that too often follow an unclear mammogram result. Launching the program in the Bay Area, a region defined by its density of biotech, healthcare, and research institutions, is a pivotal next step for the initiative.